FGFR4 and anemia: Moreover, as studies indicate anti-FGFR4 therapy may be beneficial toward cardiomyopathy (Grabner et al., 2015), our data suggest these same beneficial outcomes for inflammation, anemia, and skeletal muscle wasting would not apply.